MX2020006514A - Vacunas liquidas de virus vivos envueltos. - Google Patents
Vacunas liquidas de virus vivos envueltos.Info
- Publication number
- MX2020006514A MX2020006514A MX2020006514A MX2020006514A MX2020006514A MX 2020006514 A MX2020006514 A MX 2020006514A MX 2020006514 A MX2020006514 A MX 2020006514A MX 2020006514 A MX2020006514 A MX 2020006514A MX 2020006514 A MX2020006514 A MX 2020006514A
- Authority
- MX
- Mexico
- Prior art keywords
- liquid
- enveloped viruses
- nades
- stabilisation
- vaccine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/175—Canine distemper virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención describe una composición de vacuna líquida de un virus vivo envuelto y un vehículo farmacéuticamente aceptable, en la que el vehículo es un disolvente eutéctico profundo natural (NADES), y la vacuna tiene una actividad acuosa menor que aproximadamente 0.8. El NADES proporciona una estabilización del virus sensible durante un tiempo prolongado y a temperatura ambiente. En términos generales, las composiciones de vacuna líquida según la invención, en diferentes composiciones para los diversos virus envueltos, muestran notables capacidades de estabilización Esto supera la necesidad de liofilización, un gran beneficio económico. Además, la naturaleza líquida de las vacunas facilita la administración a blancos humanos o animales.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17210395 | 2017-12-22 | ||
PCT/EP2018/086582 WO2019122329A1 (en) | 2017-12-22 | 2018-12-21 | Liquid vaccines of live enveloped viruses |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020006514A true MX2020006514A (es) | 2020-09-07 |
Family
ID=60990579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020006514A MX2020006514A (es) | 2017-12-22 | 2018-12-21 | Vacunas liquidas de virus vivos envueltos. |
Country Status (13)
Country | Link |
---|---|
US (1) | US11344617B2 (es) |
EP (1) | EP3727440A1 (es) |
JP (1) | JP7184900B2 (es) |
CN (1) | CN111511396B (es) |
AR (1) | AR113996A1 (es) |
AU (1) | AU2018386618B2 (es) |
BR (1) | BR112020012632A2 (es) |
CA (1) | CA3084450C (es) |
CL (1) | CL2020001688A1 (es) |
MX (1) | MX2020006514A (es) |
RU (1) | RU2020123713A (es) |
WO (1) | WO2019122329A1 (es) |
ZA (1) | ZA202003155B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR113996A1 (es) * | 2017-12-22 | 2020-07-08 | Intervet Int Bv | Vacunas líquidas de virus envueltos vivos |
AR118519A1 (es) | 2019-03-29 | 2021-10-20 | Intervet Int Bv | Estabilización de la bacteria mollicutes viva en una composición líquida |
US20230102247A1 (en) * | 2020-04-28 | 2023-03-30 | President And Fellows Of Harvard College | Methods and compositions relating to ionic liquid adjuvants |
US11684594B2 (en) | 2020-05-12 | 2023-06-27 | President And Fellows Of Harvard College | Antifungal prophylaxis for cornea |
US20220010299A1 (en) * | 2020-07-13 | 2022-01-13 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and Methods to Enhance RNA Stability and Translation and Uses Thereof |
WO2022096472A1 (en) | 2020-11-04 | 2022-05-12 | Intervet International B.V. | Canine parvovirus |
WO2023118394A1 (en) | 2021-12-23 | 2023-06-29 | Intervet International B.V. | Dna vaccine against leishmaniasis |
AR127944A1 (es) | 2021-12-23 | 2024-03-13 | Intervet Int Bv | Vacunas líquidas estabilizadas de virus vivos |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101610787B (zh) * | 2006-12-15 | 2013-07-03 | 先灵-普劳有限公司 | 在培养物中复制流感病毒的方法 |
US8247198B2 (en) | 2007-09-21 | 2012-08-21 | Friedrich Srienc | Enzymatic processing in deep eutectic solvents |
US8022014B2 (en) | 2008-03-26 | 2011-09-20 | Shrieve Chemical Products, Inc. | Deep eutectic solvents and applications |
AU2011234264B2 (en) | 2010-03-31 | 2016-02-04 | Stabilitech Ltd | Excipients for stabilising viral particles, polypeptides or biological material |
DK2898890T3 (da) * | 2010-03-31 | 2019-11-25 | Stabilitech Biopharma Ltd | Stabilisering af viruspartikler |
NL2004835C2 (en) | 2010-06-07 | 2011-12-08 | Univ Leiden | Process for extracting materials from biological material. |
US9314519B2 (en) * | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
GB201303666D0 (en) | 2013-03-01 | 2013-04-17 | Goldsborough Andrew S | Sample fixation and stabilisation |
US9480739B2 (en) | 2013-03-15 | 2016-11-01 | Intervet Inc. | Bovine virus vaccines that are liquid stable |
AR099470A1 (es) | 2014-02-17 | 2016-07-27 | Intervet Int Bv | Vacunas de virus de aves de corral líquidas |
AR113996A1 (es) * | 2017-12-22 | 2020-07-08 | Intervet Int Bv | Vacunas líquidas de virus envueltos vivos |
-
2018
- 2018-12-20 AR ARP180103757A patent/AR113996A1/es unknown
- 2018-12-21 CN CN201880082809.XA patent/CN111511396B/zh active Active
- 2018-12-21 CA CA3084450A patent/CA3084450C/en active Active
- 2018-12-21 RU RU2020123713A patent/RU2020123713A/ru unknown
- 2018-12-21 AU AU2018386618A patent/AU2018386618B2/en active Active
- 2018-12-21 EP EP18829858.2A patent/EP3727440A1/en active Pending
- 2018-12-21 JP JP2020533611A patent/JP7184900B2/ja active Active
- 2018-12-21 WO PCT/EP2018/086582 patent/WO2019122329A1/en unknown
- 2018-12-21 US US16/769,820 patent/US11344617B2/en active Active
- 2018-12-21 MX MX2020006514A patent/MX2020006514A/es unknown
- 2018-12-21 BR BR112020012632-2A patent/BR112020012632A2/pt unknown
-
2020
- 2020-05-27 ZA ZA2020/03155A patent/ZA202003155B/en unknown
- 2020-06-19 CL CL2020001688A patent/CL2020001688A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US11344617B2 (en) | 2022-05-31 |
EP3727440A1 (en) | 2020-10-28 |
CA3084450C (en) | 2024-03-26 |
JP7184900B2 (ja) | 2022-12-06 |
CN111511396B (zh) | 2024-02-02 |
CL2020001688A1 (es) | 2021-01-29 |
US20200368346A1 (en) | 2020-11-26 |
CN111511396A (zh) | 2020-08-07 |
ZA202003155B (en) | 2023-02-22 |
AR113996A1 (es) | 2020-07-08 |
RU2020123713A3 (es) | 2022-01-24 |
CA3084450A1 (en) | 2019-06-27 |
JP2021508680A (ja) | 2021-03-11 |
AU2018386618A1 (en) | 2020-06-11 |
WO2019122329A1 (en) | 2019-06-27 |
RU2020123713A (ru) | 2022-01-24 |
BR112020012632A2 (pt) | 2020-12-01 |
AU2018386618B2 (en) | 2022-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020006514A (es) | Vacunas liquidas de virus vivos envueltos. | |
MX2023003875A (es) | Formulacion de una vacuna peptidica. | |
CY1120681T1 (el) | Υγρη φαρμακευτικη συνθεση | |
CY1122792T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου | |
PH12021550479A1 (en) | Dengue vaccine unit dose and administration thereof | |
EA201992784A1 (ru) | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге | |
EA201992329A1 (ru) | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге | |
CA3030422C (en) | Stabilizing excipients for therapeutic protein formulations | |
NZ707328A (en) | Virus-containing formulation and use thereof | |
PH12018502403A1 (en) | Hiv vaccine formulation | |
WO2017214596A8 (en) | Compositions and methods for preventing and treating zika virus infection | |
CU20180025A7 (es) | Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue | |
EA202090536A1 (ru) | Кристаллические формы 3-замещенного 1,2,4-оксадиазола | |
PH12017500450A1 (en) | Flavivirus virus like particle | |
PH12018501688A1 (en) | Stable liquid gonadotropin formulation | |
EA201991023A1 (ru) | Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту | |
GEP20237539B (en) | Formulations of dengue virus vaccine compositions | |
EA201890274A1 (ru) | Векторная система из аденовируса 9 птиц (fadv-9) и связанные способы | |
EA201792237A1 (ru) | Фармацевтические составы | |
MY189021A (en) | Peptides and uses therefor as antiviral agents | |
EP4219525A3 (en) | Foxm1-derived peptide, and vaccine including same | |
SG10201900933YA (en) | Koc1-derived peptide and vaccine including same | |
PE20171061A1 (es) | Composiciones farmaceuticas de accion prolongada para hepatitis c | |
WO2017007777A3 (en) | NOVEL FORMULATIONS OF PTHrP ANALOGUE | |
SG10201900879PA (en) | Cdca1-derived peptide and vaccine containing same |